Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Washing

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    61 result(s) found for: Washing. Displaying page 3 of 4.
    EudraCT Number: 2012-005409-38 Sponsor Protocol Number: TriSulfa-FPI-1 Start Date*: 2013-04-19
    Sponsor Name:Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI)
    Full Title: Pilot study phase III to evaluate the efficacy and safety of Trimethoprim-sulfamethoxazole in the treatment of idiopathic pulmonary fibrosis
    Medical condition: Ambulatory patients, men and women, with well-established diagnosis of idiopathic pulmonary fibrosis.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-002201-25 Sponsor Protocol Number: CHDR2007 Start Date*: 2020-12-14
    Sponsor Name:Centre for Human Drug Research
    Full Title: A two-part (observational and intervention) study to explore disease characteristics of vulvar (pre)malignancies compared to healthy volunteers
    Medical condition: lichen sclerosus, vulvar (pre)malignancies
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003304-39 Sponsor Protocol Number: 007 Start Date*: 2019-01-23
    Sponsor Name:Morten Rasmussen
    Full Title: Efficacy of a novel 1l PEG plus ascorbate (Plenvu) bowel preparation vs. 2l PEG plus ascorbate (Moviprep), a randomized controlled multicenter trial
    Medical condition: Bowel preparation before colonoscopy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022891 - Investigations 10017971 Gastrointestinal investigations HLGT
    21.1 10042613 - Surgical and medical procedures 10066943 Bowel preparation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-001051-12 Sponsor Protocol Number: 1708213 Start Date*: 2018-09-07
    Sponsor Name:CHU Saint-Etienne
    Full Title: VEDO - PREDIRESPUC project - Value of pharmacokinetic assays (Vedolizumab and anti-vedolizumab antibody) in the prediction of induction and maintenance therapeutic response in Ulcerative Colitis
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    20.1 100000004856 10066678 Acute ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000762-18 Sponsor Protocol Number: CRN00808-11 Start Date*: 2023-01-24
    Sponsor Name:Crinetics Pharmaceuticals, Inc.
    Full Title: A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome.
    Medical condition: Carcinoid Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10007270 Carcinoid syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002872-15 Sponsor Protocol Number: 1203/12 Start Date*: 2012-09-13
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Hyperthermic intra-peritoneal chemotherapy (HIPEC) in Ovarian cancer recurrence: Randomized trial on Survival Evaluation.
    Medical condition: Ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000732-29 Sponsor Protocol Number: CA184-124 Start Date*: 2012-04-30
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab versus Pemetrexed in Subjects with Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed Afte...
    Medical condition: NSCLC is the description of a malign development of body tissues from cells in the Bronchia / Lungs where larger cells are visible per microscope.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) HU (Prematurely Ended) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003534-25 Sponsor Protocol Number: CS8635-A-E302 Start Date*: 2009-05-13
    Sponsor Name:DAIICHI SANKYO EUROPE GmbH
    Full Title: A randomised, double-blind, parallel group study evaluating the efficacy and safety of co administration of triple combinations of olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide...
    Medical condition: Essential hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) DE (Completed) NL (Completed) ES (Completed) BE (Completed) CZ (Completed) DK (Completed) BG (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004309-15 Sponsor Protocol Number: MK-3475-604 Start Date*: 2017-05-10
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK 3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of...
    Medical condition: First-line treatment of extensive stage small cell lung cancer (ES-SCLC) in combination with standard of care (SOC) chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) PL (Completed) FR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-023963-16 Sponsor Protocol Number: 1014802/202 Start Date*: 2012-01-05
    Sponsor Name:Convergence Pharmaceuticals Ltd
    Full Title: A Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Safety and Efficacy of CNV1014802 in Patients with Trigeminal Neuragia
    Medical condition: Trigeminal neuralgia
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004852 10029227 Neuralgia trigeminal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) DK (Completed) IT (Completed) ES (Completed) LV (Completed) LT (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023310-31 Sponsor Protocol Number: MagicBullet/COLMER Start Date*: 2011-02-07
    Sponsor Name:Consorcio de apoyo a la Investigación Biomédica en Red (CAIBER)
    Full Title: Ensayo clínico en fase IV aleatorizado, abierto, multicéntrico y de no inferioridad para comparar la seguridad y la eficacia de colistina iv. con meropenem iv. en el tratamiento de la neumonía asoc...
    Medical condition: Neumonía asociada a ventilación mecánica
    Disease: Version SOC Term Classification Code Term Level
    13 10052596 Neumonia nosocomial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005905-79 Sponsor Protocol Number: OSI-774-203 Start Date*: 2007-03-13
    Sponsor Name:OSI Pharmaceuticals, Inc.
    Full Title: A Phase 2 Randomized Study of Tarceva® (erlotinib) as a Single Agent or Intercalated with Combination Chemotherapy in Patients with Newly Diagnosed Advanced Non-Small Cell Lung Cancer who have Tumo...
    Medical condition: Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001923-53 Sponsor Protocol Number: 7980 Start Date*: 2015-10-07
    Sponsor Name:Rafael Bielza Galindo
    Full Title: Intravenous iron, early functional recovery and delirium in patients atients with hip fracture
    Medical condition: Hip fracture
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022117 - Injury, poisoning and procedural complications 10020100 Hip fracture PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000852-40 Sponsor Protocol Number: TBSH-01 Start Date*: 2012-08-03
    Sponsor Name:Dermal Laboratories
    Full Title: A double-blind, placebo-controlled study determining the efficacy of terbinafine shampoo in the treatment of pityriasis capitis and seborrhoeic dermatitis.
    Medical condition: The two severe dandruff conditions to be investigated in this study are pityriasis capitis and seborrhoeic dermatitis.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10011859 Dandruff PT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10039794 Seborrhoeic dermatitis capitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-005230-15 Sponsor Protocol Number: GECP20/06 Start Date*: 2022-08-04
    Sponsor Name:Fundación GECP
    Full Title: A Phase II study of pembrolizumab, lenvatinib and chemotherapy combination in first line extensive-stage small cell lung cancer (ES-SCLC)
    Medical condition: First line treatment for extensive-stage small cell lung cancer small cell lung cancer patients (ES-SCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000471-20 Sponsor Protocol Number: RIPH_2019_01 Start Date*: 2020-11-30
    Sponsor Name:CH Tourcoing
    Full Title: Rifabutin versus rifampicin for treatment of staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy): a multicenter randomized, open-la...
    Medical condition: Adult with an staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10065011 Prosthesis related infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001111-31 Sponsor Protocol Number: 20101128 Start Date*: 2013-09-09
    Sponsor Name:Amgen Inc
    Full Title: A Phase 1b/2 Trial of AMG 386 in Combination With Pemetrexed and Carboplatin as First Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Medical condition: Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-004843-22 Sponsor Protocol Number: MK-7339-005 Start Date*: 2020-02-04
    Sponsor Name:Merck Sharp & Dohme Corp.
    Full Title: A Phase 3 Study of Pembrolizumab in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Part...
    Medical condition: Extensive Stage Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) PL (Completed) ES (Prematurely Ended) FR (Prematurely Ended) BE (Completed) HU (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002604-25 Sponsor Protocol Number: CA184-153 Start Date*: 2014-10-22
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Randomized, Multicenter, Double- Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subj...
    Medical condition: LUNG CANCER (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10025044 Lung cancer LLT
    17.1 100000004864 10029514 Non-small cell lung cancer NOS LLT
    17.1 100000004864 10041071 Small cell lung cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-007669-20 Sponsor Protocol Number: 37822681SCH2003 Start Date*: 2008-08-18
    Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: A Double-Blind, Multiple Dose Titration Study to Investigate the Safety, Tolerability and Pharmacokinetics of Once Daily and Twice Daily Doses of JNJ-37822681 in Male and Female Patients With Stabl...
    Medical condition: Schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SE (Prematurely Ended) BE (Completed) SK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 07:02:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA